BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29366445)

  • 1. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.
    Kim HB; Myung SJ
    BMB Rep; 2018 Mar; 51(3):119-125. PubMed ID: 29366445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
    Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
    Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hippo signaling pathway in liver regeneration and tumorigenesis.
    Hong L; Cai Y; Jiang M; Zhou D; Chen L
    Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):46-52. PubMed ID: 25476204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung.
    Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA
    J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuregulin 1-activated ERBB4 as a "dedicated" receptor for the Hippo-YAP pathway.
    Sudol M
    Sci Signal; 2014 Dec; 7(355):pe29. PubMed ID: 25492964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells.
    Chang Y; Fu XR; Cui M; Li WM; Zhang L; Li X; Li L; Sun ZC; Zhang XD; Li ZM; You XY; Nan FF; Wu JJ; Wang XH; Zhang MZ
    Cancer Med; 2019 Jul; 8(8):3892-3904. PubMed ID: 31124291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippo-YAP/TAZ signaling in angiogenesis.
    Park JA; Kwon YG
    BMB Rep; 2018 Mar; 51(3):157-162. PubMed ID: 29366443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The regulation and function of YAP transcription co-activator.
    Zhu C; Li L; Zhao B
    Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):16-28. PubMed ID: 25487920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs).
    Mo JS; Yu FX; Gong R; Brown JH; Guan KL
    Genes Dev; 2012 Oct; 26(19):2138-43. PubMed ID: 22972936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two faces of Hippo: activate or suppress the Hippo pathway in cancer.
    Cao J; Huang W
    Anticancer Drugs; 2017 Nov; 28(10):1079-1085. PubMed ID: 28926422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippo-YAP signaling pathway: A new paradigm for cancer therapy.
    Ma Y; Yang Y; Wang F; Wei Q; Qin H
    Int J Cancer; 2015 Nov; 137(10):2275-86. PubMed ID: 25042563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEKK2 and MEKK3 orchestrate multiple signals to regulate Hippo pathway.
    Lu J; Hu Z; Deng Y; Wu Q; Wu M; Song H
    J Biol Chem; 2021; 296():100400. PubMed ID: 33571521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines.
    Zhang X; Milton CC; Humbert PO; Harvey KF
    Cancer Res; 2009 Aug; 69(15):6033-41. PubMed ID: 19584286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense.
    Wu H; Xiao Y; Zhang S; Ji S; Wei L; Fan F; Geng J; Tian J; Sun X; Qin F; Jin C; Lin J; Yin ZY; Zhang T; Luo L; Li Y; Song S; Lin SC; Deng X; Camargo F; Avruch J; Chen L; Zhou D
    Cell Rep; 2013 May; 3(5):1663-77. PubMed ID: 23684612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
    Wong KF; Liu AM; Hong W; Xu Z; Luk JM
    Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
    Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
    PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
    Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
    Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting YAP and Hippo signaling pathway in liver cancer.
    Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
    Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.